Company to highlight integrated capabilities spanning custom material formulations, precision extrusion, catheter construction and finished-device assembly. October 13, 2026 12:57 ET  | Source: TekniPlex Wayne, PA, Oct. 13, 2026 (GLOBE NEWSWIRE) — TekniPlex Healthcare will showcase its comprehensive materials science, precision extrusion and interventional-device manufacturing capabilities at MD&M Midwest 2026, taking place October 28–29 at

October 13, 2026 08:00 ET  | Source: Acadian Seaplants Ltd. Dartmouth, Nova Scotia, Oct. 13, 2026 (GLOBE NEWSWIRE) — Acadian Animal Wellness today announced the global launch of Tasco®, an optimized feed technology for animal feed products. Based on the seaweed Ascophyllum nodosum, Tasco is a premium marine bioactive technology with prebiotic, stress-relieving, and immune-supporting

October 12, 2026 17:45 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva’s leadership will discuss its R&D pipeline, its near-term

October 12, 2026 06:00 ET  | Source: Wellcome Leap Inc. BERLIN, Oct. 12, 2026 (GLOBE NEWSWIRE) — The Gates Foundation and Wellcome Leap today announced a new initiative called Uzima: A Stillbirth Prevention Program, which aims to demonstrate that stillbirth rates can be reduced by half over the next decade across select countries. Uzima will

October 09, 2026 07:00 ET  | Source: Teva Pharmaceutical Industries Ltd Teva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m. ET PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today

October 09, 2026 00:26 ET  | Source: TherapiAI YOKOHAMA, Japan, Oct. 09, 2026 (GLOBE NEWSWIRE) — TherapiAI, a Taipei-based developer of AI agents for drug development and manufacturing, showcased its Biopharma AI Operating Layer at BioJapan 2026 this week as it works to expand its presence in Japan. Designed for biopharmaceutical companies and contract development

October 07, 2026 09:56 ET  | Source: Medela Baar, Switzerland, Oct. 07, 2026 (GLOBE NEWSWIRE) — Medela, a global leader in healthcare technology, today announced the expansion of Drainology™, a scientific initiative dedicated to advancing evidence-based chest drain management through research, education and clinical collaboration. With new digital channels, expert-led educational resources and scientific events,

October 06, 2026 04:00 ET  | Source: Smith & Nephew UK Ltd Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will take center stage at this week’s International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit

October 05, 2026 09:00 ET  | Source: Curia Global, Inc. ALBANY, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading global contract, development and manufacturing organization (CDMO), today announced a strategic investment to expand its sterile API manufacturing capabilities for both steroid and non-steroid products in Valladolid, Spain. This expansion is

October 02, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette

October 02, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a comprehensive review examining dopamine pathways in Tourette syndrome and the therapeutic potential of

October 01, 2026 03:30 ET  | Source: Boehringer Ingelheim Ingelheim, Germany – Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with obesity or overweight and type 2 diabetes (T2D).1 The trial met its co-primary endpoints, which were %

September 30, 2026 16:32 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) — TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. Mr. Rogasik will lead a global business that combines a broad API portfolio, deep scientific and technical capabilities,

September 30, 2026 09:04 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its U.S. development and manufacturing infrastructure across small molecules and peptides. The strategic initiative is a cornerstone of the

September 30, 2026 05:00 ET  | Source: Hummingbird Bioscience SINGAPORE, Sept. 30, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience (“Hummingbird”) a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced that HMBD-001 has advanced into Phase II clinical development and that the first patient in the Phase II clinical study